People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Healthtech, Other Health Care, Other, Hospitals and Physicians
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2017 |
| Sonex Health, Inc. | — | Healthtech | Series B | $22.0M | $194.4M | 2022 |
| Preceptis Medical, Inc. | — | Healthtech | Series A | $21.3M | $8.3M | 2017 |
| Celleration Inc | — | Other Health Care | Series A | $14.4M | $129.7M | 2011 |
| Vivorte Inc. | — | Biotechnology | Series A | $8.7M | $8.2M | 2015 |
| Orasi Medical Inc | — | Biotechnology | Seed | $5.3M | $78.6M | 2009 |
| Chainlink Capital Investors, LLC | — | Other | Seed | $1.1M | $5.7M | 2023 |
| West End Surgical, LLC | — | Hospitals and Physicians | Pre-Seed | $579K | $3.8M | 2023 |
| VitalMedix, Inc. | — | Biotechnology | Pre-Seed | $100K | $5.5M | 2009 |
Mark Wagner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Wagner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher Geyen | 2 | 3 |
| David Johnson | 1 | 35 |
| Robert Saunders | 1 | 18 |
| Steve Anderson | 1 | 14 |
| Jeffrey Williams | 1 | 10 |
| Peter Weiss | 1 | 9 |
| Greg Garfield | 1 | 8 |
| Buzz Benson | 1 | 8 |
| Steven Berger | 1 | 7 |
| James Sapirstein | 1 | 7 |
| George Arida | 1 | 6 |
| Jerome Zeldis | 1 | 6 |
| Richard Rosenblum | 1 | 6 |
| Kenneth Londoner | 1 | 5 |
| Peter Shagory | 1 | 5 |
| Doug Johnson | 1 | 5 |
| John Seaberg | 1 | 5 |
| Michael Jerstad | 1 | 4 |
| J. ROBERT PAULSON | 1 | 4 |
| George Emont | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.